<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DACOGEN- decitabine injection, powder, lyophilized, for solution </strong><br>Eisai Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">
<span class="Bold">These highlights do not include all the information needed to use Dacogen safely and effectively. See full prescribing information for Dacogen.</span><br><br><span class="Bold">DACOGEN<span class="Sup">®</span> (decitabine) for INJECTION</span><br><span class="Bold">Initial U.S. Approval: 2006</span>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Dacogen is a nucleoside metabolic inhibitor indicated for treatment of patients with <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndromes</span> (MDS) including previously treated and untreated, <span class="Italics">de novo</span> and secondary MDS of all French-American-British subtypes (<span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span>, <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> with ringed sideroblasts, <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> with excess blasts, <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> with excess blasts in transformation, and <span class="product-label-link" type="condition" conceptid="136056" conceptname="Chronic monocytic leukemia">chronic myelomonocytic leukemia</span>) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. (<a href="#LINK_5b266b06-fd5c-4d46-ae02-893a2ff6ee90">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">There are two regimens for Dacogen administration. With either regimen it is recommended that patients be treated for a minimum of 4 cycles; however, a complete or partial response may take longer than 4 cycles.  (<a href="#LINK_30b6d0fe-9d2b-47e6-bdbf-da048bcc1e79">2</a>) </p>
<ul class="Disk">
<li>
<span class="Bold">Treatment Regimen – Option 1<br></span>Administer Dacogen at a dose of 15 mg/m<span class="Sup">2</span> by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days.  Repeat cycle every 6 weeks.  (<a href="#LINK_32d2c41b-7e99-45d3-90fe-81ec7b46aae6">2.1</a>)</li>
<li>
<span class="Bold">Treatment Regimen – Option 2<br></span>Administer Dacogen at a dose of 20 mg/m<span class="Sup">2</span> by continuous intravenous infusion over 1 hour repeated daily for 5 days.  Repeat cycle every 4 weeks. (<a href="#LINK_26bca690-49c7-4f6c-aa2b-834328ee8de0">2.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Lyophilized powder in a single-dose vial, 50 mg/vial. (<a href="#LINK_04eedd86-147d-462e-b22e-a927b627dcc8">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None
  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disk">
<li><span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>: Perform complete blood counts and platelet counts. (<a href="#LINK_c926a46e-9f18-43ec-b768-f43242d43eab">5.1</a>) 
</li>
<li>Pregnancy: Can cause fetal harm. Advise women of potential risk to the fetus (<a href="#LINK_4e606e9c-deb6-4403-a56e-883ff0431025">5.2</a>, <a href="#LINK_b5e8a138-232c-4b93-93a9-024fee1a24ae">8.1</a>) 
</li>
<li>Women of childbearing potential and men with female partners of childbearing potential should use effective contraception and avoid pregnancy (<a href="#LINK_186f0929-785d-453c-a029-4d218422a281">5.3</a>, <a href="#LINK_000d2292-72c8-4815-afc9-884bc6eb9ad8">5.4</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (&gt; 50%) are <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>. (<a href="#LINK_6b27c75a-45b5-43a0-a64a-9948c4d553f9">6.1</a>) </p>
<p class="Highlighta"><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Eisai, Inc. at 1-888-274-2378 or FDA at 1-800-FDA-1088 or </span><span class="Bold"><span class="Italics">www.fda.gov/medwatch</span></span>.
 </p>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div><div></div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 2/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Treatment Regimen – Option 1</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Treatment Regimen – Option 2</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Patients with Non-hematologic Toxicity</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Instructions for Intravenous Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Use in Pregnancy</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Use in Women of Childbearing Potential</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Use in Men</a></h2>
<h1><a href="#section-6" class="toc">
6 ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Studies Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">
8 USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">
12 CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">
13 NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">
14 CLINICAL STUDIES
</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Controlled Trial</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Single-arm Studies</a></h2>
<h1><a href="#section-14" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-15" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">
17 PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-16.1" class="toc">Instructions for Patients</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_5b266b06-fd5c-4d46-ae02-893a2ff6ee90"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">    Dacogen is indicated for treatment of patients with <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndromes</span> (MDS) including previously treated and untreated, <span class="Italics">de novo</span> and secondary MDS of all French-American-British subtypes (<span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span>, <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> with ringed sideroblasts, <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> with excess blasts, <span class="product-label-link" type="condition" conceptid="4003185" conceptname="Refractory anemia">refractory anemia</span> with excess blasts in transformation, and <span class="product-label-link" type="condition" conceptid="136056" conceptname="Chronic monocytic leukemia">chronic myelomonocytic leukemia</span>) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_30b6d0fe-9d2b-47e6-bdbf-da048bcc1e79"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">    There are two regimens for Dacogen administration. With either regimen it is recommended that patients be treated for a minimum of 4 cycles; however, a complete or partial response may take longer than 4 cycles.  </p>
<p>    Complete blood counts and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each cycle.  Liver chemistries and serum creatinine should be obtained prior to initiation of treatment.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_32d2c41b-7e99-45d3-90fe-81ec7b46aae6"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Treatment Regimen – Option 1</h2>
<p class="First">    Dacogen is administered at a dose of 15 mg/m<span class="Sup">2</span> by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days.  This cycle should be repeated every 6 weeks.  Patients may be premedicated with standard anti-emetic therapy. </p>
<p>    If hematologic recovery (ANC ≥ 1,000/μL and platelets ≥ 50,000/μL) from a previous Dacogen treatment cycle requires more than 6 weeks, then the next cycle of Dacogen therapy should be delayed and dosing temporarily reduced by following this algorithm:</p>
<ul class="Disk">
<li>Recovery requiring more than 6, but less than 8 weeks − Dacogen dosing to be delayed for up to 2 weeks and the dose temporarily reduced to 11 mg/m<span class="Sup">2  </span>every 8 hours (33 mg/m<span class="Sup">2</span>/day, 99 mg/m<span class="Sup">2</span>/cycle) upon restarting therapy.</li>
<li>Recovery requiring more than 8, but less than 10 weeks − Patient should be assessed for disease progression (by bone marrow aspirates); in the absence of progression, the Dacogen dose should be delayed up to 2 more weeks and the dose reduced to 11 mg/m<span class="Sup">2</span> every 8 hours (33 mg/m<span class="Sup">2</span>/day, 99 mg/m<span class="Sup">2</span>/cycle) upon restarting therapy, then maintained or increased in subsequent cycles as clinically indicated.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_26bca690-49c7-4f6c-aa2b-834328ee8de0"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Treatment Regimen – Option 2</h2>
<p class="First">    Dacogen is administered at a dose of 20 mg/m<span class="Sup">2</span> by continuous intravenous infusion over 1 hour repeated daily for 5 days.  This cycle should be repeated every 4 weeks.  Patients may be premedicated with standard anti-emetic therapy.   </p>
<p>    If <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> is present, subsequent treatment cycles of Dacogen should be delayed until there is hematologic recovery (ANC ≥ 1,000/μL platelets ≥ 50,000/μL ). </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7b734bd4-87cb-4a4e-ae07-f5121dc851ba"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Patients with Non-hematologic Toxicity</h2>
<p class="First">    Following the first cycle of Dacogen treatment, if any of the following non-hematologic toxicities are present, Dacogen treatment should not be restarted until the toxicity is resolved:  1) serum creatinine ≥ 2 mg/dL; 2) SGPT, total bilirubin ≥ 2 times ULN; 3) and active or uncontrolled <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c323f337-4fbd-4686-860c-70765c767e08"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Instructions for Intravenous Administration</h2>
<p class="First">    Dacogen is a cytotoxic drug and caution should be exercised when handling and preparing Dacogen.  Procedures for proper handling and disposal of antineoplastic drugs should be applied.  Several guidances on this subject have been published.<span class="Sup">1-4</span>.</p>
<p>    Dacogen should be aseptically reconstituted with 10 mL of Sterile Water for Injection (USP); upon reconstitution, each mL contains approximately 5.0 mg of decitabine at pH 6.7-7.3.  Immediately after reconstitution, the solution should be further diluted with 0.9% Sodium Chloride Injection or 5% Dextrose Injection to a final drug concentration of 0.1 - 1.0 mg/mL.  Unless used within 15 minutes of reconstitution, the diluted solution must be prepared using <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> (2˚C - 8˚C) infusion fluids and stored at 2˚C - 8˚C (36˚F - 46˚F) for up to a maximum of 4 hours until administration.</p>
<p>    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.  Do not use if there is evidence of particulate matter or discoloration.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_04eedd86-147d-462e-b22e-a927b627dcc8"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">    Dacogen (decitabine) for Injection is supplied as a sterile, lyophilized white to almost white powder, in a single-dose vial, packaged in cartons of 1 vial. Each vial contains 50 mg of decitabine.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_abb2fe1d-8c38-4c23-9ca5-ede53001a941"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">    None</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_9f6b3ac6-07a1-4ffd-8c74-b609298b3295"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c926a46e-9f18-43ec-b768-f43242d43eab"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First">    Treatment with Dacogen is associated with <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.  Complete blood and platelet counts should be performed as needed to monitor response and toxicity, but at a minimum, prior to each dosing cycle.  After administration of the recommended dosage for the first cycle, treatment for subsequent cycles should be adjusted<span class="Italics"> [see Dosage and Administration (<a href="#LINK_32d2c41b-7e99-45d3-90fe-81ec7b46aae6">2.1</a>, <a href="#LINK_26bca690-49c7-4f6c-aa2b-834328ee8de0">2.2</a>)].</span>  Clinicians should consider the need for early institution of growth factors and/or antimicrobial agents for the prevention or treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in patients with MDS.  <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span> and worsening <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> may occur more frequently in the first or second treatment cycles, and may not necessarily indicate progression of underlying MDS.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4e606e9c-deb6-4403-a56e-883ff0431025"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Use in Pregnancy</h2>
<p class="First">    Dacogen can cause fetal harm when administered to a pregnant woman.  Based on its mechanism of action, Dacogen is expected to result in adverse reproductive effects.  In preclinical studies in mice and rats, decitabine was teratogenic, fetotoxic, and embryotoxic. There are no adequate and well-controlled studies of Dacogen in pregnant women.  If this drug is used during pregnancy, or if a patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus.  Women of childbearing potential should be advised to avoid becoming pregnant while taking Dacogen <span class="Italics">[see Use in Specific Populations (<a href="#LINK_b5e8a138-232c-4b93-93a9-024fee1a24ae">8.1</a>)]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_186f0929-785d-453c-a029-4d218422a281"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Use in Women of Childbearing Potential</h2>
<p class="First">    Women of childbearing potential should be advised to avoid becoming pregnant while receiving Dacogen and for 1 month following completion of treatment. Women of childbearing potential should be counseled to use effective contraception during this time <span class="Italics">[see Use in Specific Populations (<a href="#LINK_b5e8a138-232c-4b93-93a9-024fee1a24ae">8.1</a>)]</span>. Based on its mechanism of action, Dacogen can cause fetal harm if used during pregnancy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_000d2292-72c8-4815-afc9-884bc6eb9ad8"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Use in Men</h2>
<p class="First">    Men should be advised not to father a child while receiving treatment with Dacogen, and for 2 months following completion of treatment <span class="Italics">[see Nonclinical Toxicology (<a href="#LINK_6e12c1c0-16b8-46a7-a760-fdfb87bfbde6">13.1</a>)]</span>. Men with female partners of childbearing potential should use effective contraception during this time. Based on its mechanism of action, Dacogen alters DNA synthesis and can cause fetal harm.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_31473225-65bc-42bd-94ae-a611e2aa9a7d"></a><a name="section-6"></a><p></p>
<h1>
6 ADVERSE REACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6b27c75a-45b5-43a0-a64a-9948c4d553f9"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Studies Experience</h2>
<p class="First">    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p><span class="Italics">Most Commonly Occurring Adverse Reactions:</span>  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">pyrexia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>.</p>
<p><span class="Italics">Adverse Reactions Most Frequently <span class="Italics">(≥ 1%) </span>Resulting in Clinical Intervention in the Phase 3 Trials in the Dacogen Arm:</span></p>
<ul class="Disk">
<li>Discontinuation:  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="4190193" conceptname="Infection due to Mycobacterium intracellulare">Mycobacterium avium complex infection</span>, cardio-<span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, increased blood bilirubin, <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>. 
</li>
<li>Dose Delayed:  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, central line <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span>. 
</li>
<li>Dose Reduced:  <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>.</li>
</ul>
<p><span class="Italics">Discussion of Adverse Reactions Information<br>    </span>Dacogen was studied in 3 single-arm studies (N = 66, N = 98, N = 99) and 1 controlled supportive care study (N = 83 Dacogen, N = 81 supportive care ).  The data described below reflect exposure to Dacogen in 83 patients in the MDS trial.  In the trial, patients received 15 mg/m<span class="Sup">2</span> intravenously every 8 hours for 3 days every 6 weeks.  The median number of Dacogen cycles was 3 (range 0 to 9).</p>
<p>Table 1 presents all adverse events regardless of causality occurring in at least 5% of patients in the Dacogen group and at a rate greater than supportive care.</p>
<table>
<caption><span>Table 1 Adverse Events Reported in ≥ 5% of Patients in the Dacogen Group and at a Rate Greater than Supportive Care in Phase 3 MDS Trial </span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">  </th>
<th class="Botrule">Dacogen<br>N = 83 (%) </th>
<th class="Botrule Lrule Rrule" align="center">Supportive Care<br>N = 81 (%) </th>
</tr></thead>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">Blood and lymphatic system disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  75 (90) </td>
<td class="Botrule Lrule Rrule" align="center">  58 (72) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  74 (89) </td>
<td class="Botrule Lrule Rrule" align="center">  64 (79) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  68 (82) </td>
<td class="Botrule Lrule Rrule" align="center">  60 (74) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  24 (29) </td>
<td class="Botrule Lrule Rrule" align="center">  5 (6) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  23 (28) </td>
<td class="Botrule Lrule Rrule" align="center">  11 (14) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">Lymphadenopathy</span> </td>
<td class="Botrule Lrule Rrule" align="center">  10 (12) </td>
<td class="Botrule Lrule Rrule" align="center">  6 (7) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocythemia</span></td>
<td class="Botrule Lrule Rrule" align="center"> 4 (5)</td>
<td class="Botrule Lrule Rrule" align="center"> 1 (1)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Pulmonary edema</span> NOS</td>
<td class="Botrule Lrule Rrule" align="center"> 5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0) </td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision blurred</span></td>
<td class="Botrule Lrule Rrule" align="center"> 5 (6)</td>
<td class="Botrule Lrule Rrule" align="center"> 0 (0)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="Botrule Lrule Rrule" align="center">  35 (42) </td>
<td class="Botrule Lrule Rrule" align="center">13 (16)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td class="Botrule Lrule Rrule" align="center">  29 (35) </td>
<td class="Botrule Lrule Rrule" align="center">11 (14)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  28 (34) </td>
<td class="Botrule Lrule Rrule" align="center">13 (16)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  21 (25) </td>
<td class="Botrule Lrule Rrule" align="center">7 (9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  12 (14) </td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4330466" conceptname="Bleeding from mouth">Oral mucosal petechiae</span> </td>
<td class="Botrule Lrule Rrule" align="center">  11 (13) </td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span> </td>
<td class="Botrule Lrule Rrule" align="center">  10 (12) </td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  10 (12) </td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="200528" conceptname="Ascites">Ascites</span> </td>
<td class="Botrule Lrule Rrule" align="center">  8 (10) </td>
<td class="Botrule Lrule Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">Gingival bleeding</span></td>
<td class="Botrule Lrule Rrule" align="center"> 7 (8)</td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">Hemorrhoids</span></td>
<td class="Botrule Lrule Rrule" align="center"> 7 (8)</td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Loose stools</span></td>
<td class="Botrule Lrule Rrule" align="center"> 6 (7)</td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4278836" conceptname="Ulcer on tongue">Tongue ulceration</span></td>
<td class="Botrule Lrule Rrule" align="center"> 6 (7)</td>
<td class="Botrule Lrule Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td class="Botrule Lrule Rrule" align="center"> 5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="43530620" conceptname="Oral lesion">Oral soft tissue disorder</span> NOS</td>
<td class="Botrule Lrule Rrule" align="center"> 5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4271702" conceptname="Lip ulcer">Lip ulceration</span></td>
<td class="Botrule Lrule Rrule" align="center"> 4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">Abdominal distension</span></td>
<td class="Botrule Lrule Rrule" align="center"> 4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Botrule Lrule Rrule" align="center"> 4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Gastro-<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">esophageal reflux</span> disease</td>
<td class="Botrule Lrule Rrule" align="center"> 4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="441334" conceptname="Glossodynia">Glossodynia</span></td>
<td class="Botrule Lrule Rrule" align="center"> 4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">General disorders and administrative site disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  44 (53) </td>
<td class="Botrule Lrule Rrule" align="center">23 (28)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span> </td>
<td class="Botrule Lrule Rrule" align="center">  21 (25) </td>
<td class="Botrule Lrule Rrule" align="center">13 (16)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span> </td>
<td class="Botrule Lrule Rrule" align="center">  18 (22) </td>
<td class="Botrule Lrule Rrule" align="center">14 (17)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  15 (18) </td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  11 (13) </td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span> </td>
<td class="Botrule Lrule Rrule" align="center">  10 (12) </td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">Tenderness</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  9 (11) </td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">Fall</span></td>
<td class="Botrule Lrule Rrule" align="center">7 (8)</td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (7)</td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Intermittent pyrexia</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span></td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Crepitations NOS</td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Catheter site <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Catheter site <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4319319" conceptname="Injection site edema">Injection site swelling</span></td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">Hepatobiliary disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4032334" conceptname="Hyperbilirubinemia">Hyperbilirubinemia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  12 (14) </td>
<td class="Botrule Lrule Rrule" align="center">  4 (5) </td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  18 (22) </td>
<td class="Botrule Lrule Rrule" align="center">  11 (14) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span> </td>
<td class="Botrule Lrule Rrule" align="center">  10 (12) </td>
<td class="Botrule Lrule Rrule" align="center">  6 (7) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candidal infection</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  8 (10) </td>
<td class="Botrule Lrule Rrule" align="center">  1 (1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Catheter related <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span></td>
<td class="Botrule Lrule Rrule" align="center">7 (8)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span> NOS</td>
<td class="Botrule Lrule Rrule" align="center">6 (7)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="435459" conceptname="Staphylococcal infectious disease">Staphylococcal infection</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (7)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral candidiasis</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> NOS</td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">Bacteremia</span></td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="440603" conceptname="Blood transfusion reaction">Transfusion reaction</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (7)</td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4269361" conceptname="Friction burn">Abrasion</span> NOS</td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">Investigations</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">Cardiac murmur</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  13 (16) </td>
<td class="Botrule Lrule Rrule" align="center">  9 (11) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Blood alkaline phosphatase NOS increased  </td>
<td class="Botrule Lrule Rrule" align="center">  9 (11) </td>
<td class="Botrule Lrule Rrule" align="center">  7 (9) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased </td>
<td class="Botrule Lrule Rrule" align="center">  8 (10) </td>
<td class="Botrule Lrule Rrule" align="center">  7 (9) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Blood urea increased </td>
<td class="Botrule Lrule Rrule" align="center">  8 (10) </td>
<td class="Botrule Lrule Rrule" align="center">  1 (1) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Blood lactate dehydrogenase increased</td>
<td class="Botrule Lrule Rrule" align="center">7 (8) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">5 (6)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Blood albumin decreased</td>
<td class="Botrule Lrule Rrule" align="center">6 (7) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">0 (0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Blood <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> increased</td>
<td class="Botrule Lrule Rrule" align="center">5 (6) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Blood chloride decreased</td>
<td class="Botrule Lrule Rrule" align="center">5 (6) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Protein total decreased</td>
<td class="Botrule Lrule Rrule" align="center">4 (5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Blood <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> decreased</td>
<td class="Botrule Lrule Rrule" align="center">4 (5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Blood bilirubin decreased</td>
<td class="Botrule Lrule Rrule" align="center">4 (5) </td>
<td class="Botrule Lrule Rrule Toprule" align="center">1 (1)</td>
</tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="3"> <span class="Bold">Metabolism and nutrition disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  27 (33) </td>
<td class="Botrule Lrule Rrule" align="center">16 (20)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4001047" conceptname="Hypoalbuminemia">Hypoalbuminemia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  20 (24) </td>
<td class="Botrule Lrule Rrule" align="center">14 (17)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  20 (24) </td>
<td class="Botrule Lrule Rrule" align="center">6 (7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  18 (22) </td>
<td class="Botrule Lrule Rrule" align="center">10 (12)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">Hyponatremia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  16 (19) </td>
<td class="Botrule Lrule Rrule" align="center">13 (16)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Appetite decreased</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  13 (16) </td>
<td class="Botrule Lrule Rrule" align="center">12 (15)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  13 (16) </td>
<td class="Botrule Lrule Rrule" align="center">8 (10)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">Hyperkalemia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  11 (13) </td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  17 (20) </td>
<td class="Botrule Lrule Rrule" align="center">  8 (10) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in limb</span> </td>
<td class="Botrule Lrule Rrule" align="center">  16 (19) </td>
<td class="Botrule Lrule Rrule" align="center">  8 (10) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> </td>
<td class="Botrule Lrule Rrule" align="center">  14 (17) </td>
<td class="Botrule Lrule Rrule" align="center">  5 (6) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4010016" conceptname="Chest wall pain">Chest wall pain</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (7)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Musculoskeletal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td class="Botrule Lrule Rrule" align="center">  23 (28) </td>
<td class="Botrule Lrule Rrule" align="center">  11 (14) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td class="Botrule Lrule Rrule" align="center">  15 (18) </td>
<td class="Botrule Lrule Rrule" align="center">  10 (12) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  9 (11) </td>
<td class="Botrule Lrule Rrule" align="center">  1 (1) </td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">Psychiatric disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  23 (28) </td>
<td class="Botrule Lrule Rrule" align="center">  11 (14) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span> </td>
<td class="Botrule Lrule Rrule" align="center">  10 (12) </td>
<td class="Botrule Lrule Rrule" align="center">  3 (4) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span> </td>
<td class="Botrule Lrule Rrule" align="center">  9 (11) </td>
<td class="Botrule Lrule Rrule" align="center">  8 (10) </td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">Renal and urinary disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary frequency</span></td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> </td>
<td class="Botrule Lrule Rrule" align="center">  33 (40) </td>
<td class="Botrule Lrule Rrule" align="center">25 (31)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> </td>
<td class="Botrule Lrule Rrule" align="center">  13 (16) </td>
<td class="Botrule Lrule Rrule" align="center">6 (7)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Crackles lung</span> </td>
<td class="Botrule Lrule Rrule" align="center">  12 (14) </td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="73026" conceptname="Abnormal breath sounds">Breath sounds decreased</span> </td>
<td class="Botrule Lrule Rrule" align="center">  8 (10) </td>
<td class="Botrule Lrule Rrule" align="center">7 (9)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">Hypoxia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  8 (10) </td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span></td>
<td class="Botrule Lrule Rrule" align="center">7 (8)</td>
<td class="Botrule Lrule Rrule" align="center">2 (2)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="257683" conceptname="Posterior rhinorrhea">Postnasal drip</span></td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">2 (2)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold">Skin and subcutaneous tissue disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span> </td>
<td class="Botrule Lrule Rrule" align="center">  18 (22) </td>
<td class="Botrule Lrule Rrule" align="center">  12 (15) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  16 (19) </td>
<td class="Botrule Lrule Rrule" align="center">  7 (9) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> </td>
<td class="Botrule Lrule Rrule" align="center">  12 (14) </td>
<td class="Botrule Lrule Rrule" align="center">  5 (6) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">Skin lesion</span> NOS </td>
<td class="Botrule Lrule Rrule" align="center">  9 (11) </td>
<td class="Botrule Lrule Rrule" align="center">  3 (4) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Pruritis </td>
<td class="Botrule Lrule Rrule" align="center">  9 (11) </td>
<td class="Botrule Lrule Rrule" align="center">  2 (2) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td class="Botrule Lrule Rrule" align="center">7 (8)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span> NOS</td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">1 (1)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4133326" conceptname="Facial swelling">Swelling face</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">0 (0)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="3"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> </td>
<td class="Botrule Lrule Rrule" align="center">  32 (39) </td>
<td class="Botrule Lrule Rrule" align="center">  13 (16) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span> </td>
<td class="Botrule Lrule Rrule" align="center">  19 (23) </td>
<td class="Botrule Lrule Rrule" align="center">  10 (12) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> NOS</td>
<td class="Botrule Lrule Rrule" align="center">5 (6)</td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span> NOS</td>
<td class="Botrule Lrule Rrule" align="center">4 (5)</td>
<td class="Botrule Lrule Rrule" align="center">3 (4)</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">    Discussion of Clinically Important Adverse Reactions<br>    </span></span>In the controlled trial using Dacogen dosed at 15 mg/m<span class="Sup">2</span>, administered by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days, the highest incidence of Grade 3 or Grade 4 adverse events in the Dacogen arm were <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (87%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (85%), <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">febrile neutropenia</span> (23%) and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (22%).  Bone marrow suppression was the most frequent cause of dose reduction, delay and discontinuation.  Six patients had fatal events associated with their underlying disease and <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> (<span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>) that were considered at least possibly related to drug treatment [See <span class="Italics">Warnings and Precautions (<a href="#LINK_c926a46e-9f18-43ec-b768-f43242d43eab">5.1</a>)</span>]. Of the 83 Dacogen-treated patients, 8 permanently discontinued therapy for adverse events; compared to 1 of 81 patients in the supportive care arm.</p>
<p>    In a single-arm MDS study (N=99) Dacogen was dosed at 20 mg/m<span class="Sup">2</span> intravenous, infused over one hour daily for 5 consecutive days of a 4 week cycle. Table 2 presents all adverse events regardless of causality occurring in at least 5% of patients. </p>
<table>
<caption><span>Table 2 Adverse Events Reported in ≥ 5% of Patients in a Single-arm Study* </span></caption>
<col>
<col>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">  </th>
<th class="Rrule">Dacogen<br>N = 99 (%) </th>
</tr></thead>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">Blood and lymphatic system disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> </td>
<td class="Botrule Lrule Rrule" align="center">31 (31%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4250734" conceptname="Febrile neutropenia">Febrile neutropenia</span> </td>
<td class="Botrule Lrule Rrule" align="center">20 (20%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">Neutropenia</span></td>
<td class="Botrule Lrule Rrule" align="center">38 (38% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">Pancytopenia</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocythemia</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> </td>
<td class="Botrule Lrule Rrule" align="center">27 (27%)</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Cardiac failure congestive</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">Tachycardia</span></td>
<td class="Botrule Lrule Rrule" align="center">8 (8% )</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">Ear and labyrinth disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="380733" conceptname="Otalgia">Ear pain</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> </td>
<td class="Botrule Lrule Rrule" align="center">  14 (14%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal pain upper</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> </td>
<td class="Botrule Lrule Rrule" align="center">  30 (30%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> </td>
<td class="Botrule Lrule Rrule" align="center">  28 (28%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  10 (10%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Gastro-<span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">esophageal reflux</span> disease</td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> </td>
<td class="Botrule Lrule Rrule" align="center">  40 (40%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">Oral pain</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span> </td>
<td class="Botrule Lrule Rrule" align="center">  11 (11%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4099176" conceptname="Toothache">Toothache</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> </td>
<td class="Botrule Lrule Rrule" align="center">  16 (16%) </td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">General disorders and administration site conditions</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  15 (15%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Chills</span> </td>
<td class="Botrule Lrule Rrule" align="center">  16 (16%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span> </td>
<td class="Botrule Lrule Rrule" align="center">  46 (46%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="432661" conceptname="Inflammatory disease of mucous membrane">Mucosal inflammation</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (9% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema peripheral</span> </td>
<td class="Botrule Lrule Rrule" align="center">  27 (27%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  36 (36%) </td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">Cellulitis</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (9% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral candidiasis</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  20 (20%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4327861" conceptname="Bacteremia due to Staphylococcus aureus">Staphylococcal bacteremia</span></td>
<td class="Botrule Lrule Rrule" align="center">8 (8% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4103655" conceptname="Dental abscess">Tooth abscess</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span> </td>
<td class="Botrule Lrule Rrule" align="center">  10 (10%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td class="Botrule Lrule Rrule" align="center">7 (7% )</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> and procedural complications</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (9% )</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">Investigations</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      Blood bilirubin increased</td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="73026" conceptname="Abnormal breath sounds">Breath sounds abnormal</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decreased</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (9% )</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">Metabolism and nutrition disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> </td>
<td class="Botrule Lrule Rrule" align="center">23 (23%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Lrule Rrule" align="center">8 (8% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span></td>
<td class="Botrule Lrule Rrule" align="center">8 (8% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> </td>
<td class="Botrule Lrule Rrule" align="center">12 (12%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4098604" conceptname="Hypomagnesemia">Hypomagnesemia</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  17 (17%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> </td>
<td class="Botrule Lrule Rrule" align="center">  18 (18%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Bone pain</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Muscle spasms</span></td>
<td class="Botrule Lrule Rrule" align="center">7 (7% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscular weakness</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (9% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span> </td>
<td class="Botrule Lrule Rrule" align="center">  18 (18%) </td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> </td>
<td class="Botrule Lrule Rrule" align="center">  21 (21%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> </td>
<td class="Botrule Lrule Rrule" align="center">  23 (23%) </td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">Psychiatric disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (9% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusional state</span></td>
<td class="Botrule Lrule Rrule" align="center">8 (8% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (9% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> </td>
<td class="Botrule Lrule Rrule" align="center">  14 (14%) </td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span> </td>
<td class="Botrule Lrule Rrule" align="center">  27 (27%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span> </td>
<td class="Botrule Lrule Rrule" align="center">  29 (29%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span> </td>
<td class="Botrule Lrule Rrule" align="center">  13 (13%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Botrule Lrule Rrule" align="center">8 (8% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="254061" conceptname="Pleural effusion">Pleural effusion</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4220211" conceptname="Congestion of nasal sinus">Sinus congestion</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold">Skin and subcutaneous tissue disorders</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span></td>
<td class="Botrule Lrule Rrule" align="center">8 (8% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (9% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4181178" conceptname="Night sweats">Night sweats</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">Petechiae</span> </td>
<td class="Botrule Lrule Rrule" align="center">  12 (12%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Botrule Lrule Rrule" align="center">9 (9% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> </td>
<td class="Botrule Lrule Rrule" align="center">  11 (11%) </td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="4316083" conceptname="Skin lesion">Skin lesion</span></td>
<td class="Botrule Lrule Rrule" align="center">5 (5% )</td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="2"> <span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td class="Botrule Lrule Rrule" align="center">6 (6% )</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> </td>
<td class="Botrule Lrule Rrule" align="center">  11 (11%) </td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="2"> * In this single arm study, investigators reported adverse events based on clinical signs and symptoms rather <br>than predefined laboratory abnormalities. Thus not all laboratory abnormalities were recorded as adverse events.</td></tr>
</tbody>
</table>
<p><span class="Italics">    Discussion of Clinically Important Adverse Reactions<br>    </span>In the single-arm study (N=99) when Dacogen was dosed at 20 mg/m<span class="Sup">2</span> intravenous, infused over one hour daily for 5 consecutive days, the highest incidence of Grade 3 or Grade 4 adverse events were <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (37%), <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (24%) and <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> (22%).  Seventy-eight percent of patients had dose delays, the median duration of this delay was 7 days and the largest percentage of delays were due to hematologic toxicities.  Hematologic toxicities and <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> were the most frequent causes of dose delays and discontinuation.  Eight patients had fatal events due to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and/or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (seven of which occurred in the clinical setting of <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>) that were considered at least possibly related to drug treatment.  Nineteen of 99 patients permanently discontinued therapy for adverse events.</p>
<p>    No overall difference in safety was detected between patients &gt; 65 years of age and younger patients in these <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplasia</span> trials.  No significant gender differences in safety or efficacy were detected.  Patients with renal or hepatic dysfunction were not studied.  Insufficient numbers of non-white patients were available to draw conclusions in these clinical trials.</p>
<p>    Serious Adverse Events that occurred in patients receiving Dacogen regardless of causality, not previously reported in <span class="Bold"><span class="Underline">Tables 1 and 2 </span></span>include:</p>
<ul class="Disk">
<li>Blood and Lymphatic System Disorders:  <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="200527" conceptname="Splenomegaly">splenomegaly</span>. 
</li>
<li><span class="product-label-link" type="condition" conceptid="321588" conceptname="Heart disease">Cardiac Disorders</span>:  <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, cardio-<span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="321319" conceptname="Cardiomyopathy">cardiomyopathy</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>. 
</li>
<li><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>:  <span class="product-label-link" type="condition" conceptid="4009488" conceptname="Sore gums">gingival pain</span>, <span class="product-label-link" type="condition" conceptid="4291649" conceptname="Upper gastrointestinal hemorrhage">upper gastrointestinal hemorrhage</span>. 
</li>
<li>General Disorders and Administrative Site Conditions:  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, catheter site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. 
</li>
<li>Hepatobiliary Disorders:  <span class="product-label-link" type="condition" conceptid="192956" conceptname="Cholecystitis">cholecystitis</span>. 
</li>
<li><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span>:  <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infection</span>, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span>, <span class="product-label-link" type="condition" conceptid="261053" conceptname="Pneumonia in aspergillosis">bronchopulmonary aspergillosis</span>, <span class="product-label-link" type="condition" conceptid="4057947" conceptname="Paracolic abscess">peridiverticular abscess</span>, <span class="product-label-link" type="condition" conceptid="4170143" conceptname="Respiratory tract infection">respiratory tract infection</span>, pseudomonal <span class="product-label-link" type="condition" conceptid="4028389" conceptname="Infectious disease of lung">lung infection</span>, <span class="product-label-link" type="condition" conceptid="4190193" conceptname="Infection due to Mycobacterium intracellulare">Mycobacterium avium complex infection</span>. 
</li>
<li>Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">Poisoning</span> and Procedural Complications:  <span class="product-label-link" type="condition" conceptid="439502" conceptname="Postoperative pain">post procedural pain</span>, <span class="product-label-link" type="condition" conceptid="4002836" conceptname="Postoperative hemorrhage">post procedural hemorrhage</span>. 
</li>
<li><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:  <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>. 
</li>
<li>Psychiatric Disorders:  <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>. 
</li>
<li>Renal and Urinary Disorders:  <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, <span class="product-label-link" type="condition" conceptid="4096556" conceptname="Bleeding from urethra">urethral hemorrhage</span>. 
</li>
<li>Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span>:  <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, lung infiltration, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, <span class="product-label-link" type="condition" conceptid="4203096" conceptname="Lung mass">pulmonary mass</span>. 
</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reaction</span>:  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> (<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>) to Dacogen has been reported in a Phase 2 trial.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_147dce7b-63bb-49f6-916a-35136ec17b33"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-marketing Experience</h2>
<p class="First">    The following adverse reactions have been identified during post-approval use of Dacogen.  Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>Cases of Sweet’s Syndrome (<span class="product-label-link" type="condition" conceptid="4225434" conceptname="Acute febrile neutrophilic dermatosis">acute febrile neutrophilic dermatosis</span>) have been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_693510ab-3b84-4729-927b-84bc71b224b8"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">    Drug interaction studies with decitabine have not been conducted.  <span class="Italics">In vitro</span> studies in human liver microsomes suggest that decitabine is unlikely to inhibit or induce cytochrome P450 enzymes.  <span class="Italics">In vitro</span> metabolism studies have suggested that decitabine is not a substrate for human liver cytochrome P450 enzymes.  As plasma protein binding of decitabine is negligible (&lt;1%), interactions due to displacement of more highly protein bound drugs from plasma proteins are not expected.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_2e65707e-8440-4f57-a3bd-f92d5bd75f81"></a><a name="section-8"></a><p></p>
<h1>
8 USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_b5e8a138-232c-4b93-93a9-024fee1a24ae"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">    Dacogen can cause fetal harm when administered to a pregnant woman.  There are no adequate and well-controlled studies of Dacogen in pregnant women.</p>
<p>    The developmental toxicity of decitabine was examined in mice exposed to single IP (intraperitoneal) injections (0, 0.9 and 3.0 mg/m<span class="Sup">2</span>, approximately 2% and 7% of the recommended daily clinical dose, respectively) over gestation days 8, 9, 10 or 11.  No maternal toxicity was observed but reduced fetal survival was observed after treatment at 3 mg/m<span class="Sup">2</span> and decreased fetal weight was observed at both dose levels.  The 3 mg/m<span class="Sup">2</span> dose elicited characteristic fetal defects for each treatment day, including supernumerary ribs (both dose levels), fused vertebrae and ribs, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, vertebral defects, hind-<span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb defects</span> and digital defects of fore- and hind-limbs.  In rats given a single IP injection of 2.4, 3.6 or 6 mg/m<span class="Sup">2</span> (approximately 5, 8, or 13% the daily recommended clinical dose, respectively) on gestation days 9-12, no maternal toxicity was observed.  No live fetuses were seen at any dose when decitabine was injected on gestation day 9.  A significant decrease in fetal survival and reduced fetal weight at doses greater than 3.6 mg/m<span class="Sup">2</span> was seen when decitabine was given on gestation day 10.  Increased incidences of vertebral and rib anomalies were seen at all dose levels, and induction of exophthalmia, <span class="product-label-link" type="condition" conceptid="4309376" conceptname="Exencephaly">exencephaly</span>, and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> were observed at 6.0 mg/m<span class="Sup">2</span>.  Increased incidence of foredigit defects was seen in fetuses at doses greater than 3.6 mg/m<span class="Sup">2</span>.  Reduced size and ossification of long bones of the fore-limb and hind-limb were noted at 6.0 mg/m<span class="Sup">2</span>.  If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus.  Women of child bearing potential should be advised to avoid becoming pregnant while taking Dacogen.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_0747f923-1935-4d1d-8d41-fddc5e3c03fe"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">    It is not known whether decitabine or its metabolites are excreted in human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions from Dacogen in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_bf20eb49-65ef-4b2b-ac1f-e1fa2496b69b"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">    The safety and effectiveness of Dacogen in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_b76f81a3-182e-4e03-a324-4764857fa3bd"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">    Of the total number of patients exposed to Dacogen in the controlled clinical trial, 61 of 83 patients were age 65 and over, while 21 of 83 patients were age 75 and over.  No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1b76f820-31ee-4ec6-b91b-3ca84ebf766b"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">    There are no data on the use of Dacogen in patients with renal dysfunction; therefore, Dacogen should be used with caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_57a7d188-9c37-4a65-928e-15b4224de721"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">    There are no data on the use of Dacogen in patients with hepatic dysfunction; therefore, Dacogen should be used with caution in these patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_c2da9fa8-a146-419e-ba8c-22448f141d39"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">    There is no known antidote for overdosage with Dacogen.  Higher doses are associated with increased <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span> including prolonged <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.  Standard supportive measures should be taken in the event of an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_4c5297ff-0ff4-40f9-9568-1e3a4f730929"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">    Dacogen (decitabine) for Injection contains decitabine (5-aza-2’-deoxycitidine), an analogue of the natural nucleoside 2’-deoxycytidine.  Decitabine is a fine, white to almost white powder with the molecular formula of C<span class="Sub">8</span>H<span class="Sub">12</span>N<span class="Sub">4</span>O<span class="Sub">4</span> and a molecular weight of 228.21.  Its chemical name is 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1<span class="Italics">H</span>)-one and it has the following structural formula:</p>
<div class="Figure"><img alt="Dacogen structural formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2&amp;name=dacogen-1.jpg"></div>
<p>    Decitabine is slightly soluble in ethanol/water (50/50), methanol/water (50/50) and methanol; sparingly soluble in water and soluble in dimethylsulfoxide (DMSO).</p>
<p>    Dacogen (decitabine) for Injection is a white to almost white sterile lyophilized powder supplied in a clear colorless glass vial. Each 20 mL, single dose, glass vial contains 50 mg decitabine, 68 mg monobasic potassium phosphate (potassium dihydrogen phosphate) and 11.6 mg sodium hydroxide. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_17767bc0-f040-4d26-97bc-2d54700cda55"></a><a name="section-11"></a><p></p>
<h1>
12 CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_54a85e44-0ce1-4517-a47c-5dd820e77adb"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">    Decitabine is believed to exert its antineoplastic effects after phosphorylation and direct incorporation into DNA and inhibition of DNA methyltransferase, causing hypomethylation of DNA and cellular differentiation or <span class="product-label-link" type="condition" conceptid="4048757" conceptname="Apoptosis">apoptosis</span>.  Decitabine inhibits DNA methylation <span class="Italics">in vitro,</span> which is achieved at concentrations that do not cause major suppression of DNA synthesis.  Decitabine-induced hypomethylation in neoplastic cells may restore normal function to genes that are critical forthe control of cellulardifferentiation and proliferation.  In rapidly dividing cells, the cytotoxicity of decitabine may also be attributed to the formation of covalent adducts between DNA methyltransferase and decitabine incorporated into DNA.  Non-proliferating cells are relatively insensitive to decitabine.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_815a7b99-726b-44b3-b246-b6d4bb592e95"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">    Decitabine has been shown to induce hypomethylation both in vitro and in vivo.  However, there have been no studies of decitabine-induced hypomethylation and pharmacokinetic parameters.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_fef1e73f-5b71-4994-8cb5-c39bbd800382"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">    Pharmacokinetic parameters were evaluated in patients. Eleven patients received 20 mg/m<span class="Sup">2</span> infused over 1 hour intravenously (treatment Option 2), Fourteen patients received 15 mg/m<span class="Sup">2</span> infused over 3 hours (treatment Option 1). PK parameters are shown in Table 3.  Plasma concentration-time profiles after discontinuation of infusion showed a biexponential decline.  The CL of decitabine was higher following treatment Option 2.  Upon repeat doses there was no systemic accumulation of decitabine or any changes in PK parameters.  Population PK analysis (N=35) showed that the cumulative AUC per cycle for treatment Option 2 was 2.3-fold lower than the cumulative AUC per cycle following treatment Option 1.</p>
<table>
<caption><span>Table 3 Mean (CV% or 95% CI) Pharmacokinetic Parameters of Decitabine </span></caption>
<col>
<col>
<col>
<col>
<col>
<col>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">Dose </th>
<th class="Botrule Lrule Rrule" align="center">C<span class="Sub">max</span><br>(ng/mL) </th>
<th class="Botrule Lrule Rrule" align="center">AUC<span class="Sub">0-∞</span><br>(ng·h/mL) </th>
<th class="Botrule Lrule Rrule" align="center">T<span class="Sub">1/2</span><br>(h) </th>
<th class="Botrule Lrule Rrule" align="center">CL<br>(L/h/m<span class="Sup">2</span>) </th>
<th class="Botrule Lrule Rrule" align="center">AUC<span class="Sub">Cumulative</span>***<br>(ng·h/mL) </th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="6">  *N=14, **N=11, ***N=35 Cumulative AUC per cycle </td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule">  15 mg/m<span class="Sup">2</span> 3-hr infusion every 8 hours for 3 days (Option 1)* </td>
<td class="Botrule Lrule Rrule" align="center">73.8<br>(66)</td>
<td class="Botrule Lrule Rrule" align="center">163<br>(62)</td>
<td class="Botrule Lrule Rrule" align="center">0.62<br>(49)</td>
<td class="Botrule Lrule Rrule" align="center">125<br>(53)</td>
<td class="Botrule Lrule Rrule" align="center">1332<br>(1010-1730)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">  20 mg/m<span class="Sup">2</span> 1-hr infusion daily for 5 days (Option 2)** </td>
<td class="Botrule Lrule Rrule" align="center">147<br>(49)</td>
<td class="Botrule Lrule Rrule" align="center">115<br>(43)</td>
<td class="Botrule Lrule Rrule" align="center">  0.54<br>(43)</td>
<td class="Botrule Lrule Rrule" align="center">210<br>(47)</td>
<td class="Botrule Lrule Rrule" align="center">570<br>(470-700)</td>
</tr>
</tbody>
</table>
<p>    The exact route of elimination and metabolic fate of decitabine is not known in humans.  One of the pathways of elimination of decitabine appears to be deamination by cytidine deaminase found principally in the liver but also in granulocytes, intestinal epithelium and whole blood.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_3ca53a5b-d3d2-44ce-adb6-ef2caa36f7ed"></a><a name="section-12"></a><p></p>
<h1>
13 NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_6e12c1c0-16b8-46a7-a760-fdfb87bfbde6"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis and Impairment of Fertility</h2>
<p class="First">    Carcinogenicity studies with decitabine have not been conducted.</p>
<p>    The mutagenic potential of decitabine was tested in several <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> systems.  Decitabine increased mutation frequency in L5178Y mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cells, and mutations were produced in an <span class="Italics">Escherichia</span><span class="Italics">coli lac-I</span> transgene in colonic DNA of decitabine-treated mice.  Decitabine caused chromosomal rearrangements in larvae of fruit flies.</p>
<p>    The effect of decitabine on postnatal development and reproductive capacity was evaluated in mice administered a single 3 mg/m<span class="Sup">2</span> IP injection (approximately 7% the recommended daily clinical dose) on day 10 of gestation.  Body weights of males and females exposed <span class="Italics">in utero</span> to decitabine were significantly reduced relative to controls at all postnatal time points.  No consistent effect on fertility was seen when female mice exposed <span class="Italics">in utero</span> were mated to untreated males.  Untreated females mated to males exposed <span class="Italics">in utero</span> showed decreased fertility at 3 and 5 months of age (36% and 0% pregnancy rate, respectively).  In male mice given IP injections of 0.15, 0.3 or 0.45 mg/m<span class="Sup">2</span> decitabine (approximately 0.3% to 1% the recommended clinical dose) 3 times a week for 7 weeks, decitabine did not affect survival, body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> or hematological measures (hemoglobin and WBC counts).  Testes weights were reduced, abnormal histology was observed and significant decreases in sperm number were found at doses ≥ 0.3 mg/m<span class="Sup">2</span>.  In females mated to males dosed with ≥ 0.3 mg/m<span class="Sup">2</span> decitabine, pregnancy rate was reduced and preimplantation loss was significantly increased.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="LINK_3444b0e7-fa2c-4089-aa9c-6fe59ba95e18"></a><a name="section-13"></a><p></p>
<h1>
14 CLINICAL STUDIES
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_197a654d-6dfb-4fdc-a0de-c5063be5a4a9"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Controlled Trial</h2>
<p class="First">    A randomized open-label, multicenter, controlled trial evaluated 170 adult patients with <span class="product-label-link" type="condition" conceptid="138994" conceptname="Myelodysplastic syndrome">myelodysplastic syndromes</span> (MDS) meeting French-American-British (FAB) classification criteria and International Prognostic Scoring System (IPSS) High-Risk, Intermediate-2 and Intermediate-1 prognostic scores. Eighty-nine patients were randomized to Dacogen therapy plus supportive care (only 83 received Dacogen), and 81 to Supportive Care (SC) alone.  Patients with <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">Acute Myeloid Leukemia</span> (AML) were not intended to be included.  Of the 170 patients included in the study, independent review (adjudicated diagnosis) found that 12 patients (9 in the Dacogen arm and 3 in the SC arm) had the diagnosis of AML at baseline.  Baseline demographics and other patient characteristics in the Intent-to-Treat (ITT) population were similar between the 2 groups, as shown in Table 4.</p>
<table>
<caption><span>Table 4 Baseline Demographics and Other Patient Characteristics (ITT)</span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<th>Demographic or Other Patient Characteristic </th>
<th align="center">Dacogen<br>N = 89 </th>
<th align="center">Supportive Care<br>N = 81 </th>
</tr></thead>
<tbody>
<tr class="First"><td colspan="3"> <span class="Bold">Age (years)</span>
</td></tr>
<tr>
<td class="Botrule"> Mean (±SD)<br> Median (IQR)<br> (Range: min-max) </td>
<td class="Botrule" align="center">69±10<br>70 (65-76)<br>(31-85)</td>
<td class="Botrule" align="center">67±10<br>70 (62-74)<br>(30-82)</td>
</tr>
<tr><td colspan="3"> <span class="Bold">Gender n (%)</span>
</td></tr>
<tr>
<td class="Botrule"> Male<br> Female </td>
<td class="Botrule" align="center">59 (66)<br>30 (34)</td>
<td class="Botrule" align="center">57 (70)<br>24 (30)</td>
</tr>
<tr><td colspan="3"> <span class="Bold">Race n (%)</span>
</td></tr>
<tr>
<td class="Botrule"> White<br> Black<br> Other </td>
<td class="Botrule" align="center">83 (93)<br>4 (4)<br>2 (2)</td>
<td class="Botrule" align="center">76 (94)<br>2 (2)<br>3 (4)</td>
</tr>
<tr><td colspan="3"> <span class="Bold">Weeks Since MDS Diagnosis</span>
</td></tr>
<tr>
<td class="Botrule"> Mean (±SD)<br> Median (IQR)<br> (Range: min-max) </td>
<td class="Botrule" align="center">86±131<br>29 (10-87)<br>(2-667)</td>
<td class="Botrule" align="center">77±119<br>35 (7-98)<br>(2-865)</td>
</tr>
<tr><td colspan="3"> <span class="Bold">Previous MDS Therapy n (%)</span>
</td></tr>
<tr>
<td class="Botrule"> Yes<br> No </td>
<td class="Botrule" align="center">27 (30)<br>62 (70)</td>
<td class="Botrule" align="center">19 (23)<br>62 (77)</td>
</tr>
<tr><td colspan="3"> <span class="Bold">RBC Transfusion Status n (%)</span>
</td></tr>
<tr>
<td class="Botrule"> Independent<br> Dependent </td>
<td class="Botrule" align="center">23 (26)<br>66 (74)</td>
<td class="Botrule" align="center">27 (33)<br>54 (67)</td>
</tr>
<tr><td colspan="3"> <span class="Bold">Platelet Transfusion Status n (%)</span>
</td></tr>
<tr>
<td class="Botrule"> Independent<br> Dependent </td>
<td class="Botrule" align="center">69 (78)<br>20 (22)</td>
<td class="Botrule" align="center">62 (77)<br>19 (23)</td>
</tr>
<tr><td colspan="3"> <span class="Bold">IPSS Classification n (%)</span>
</td></tr>
<tr>
<td class="Botrule"> Intermediate-1<br> Intermediate-2<br> High Risk </td>
<td class="Botrule" align="center">28 (31)<br>38 (43)<br>23 (26)</td>
<td class="Botrule" align="center">24 (30)<br>36 (44)<br>21 (26)</td>
</tr>
<tr><td colspan="3"> <span class="Bold">FAB Classification n (%)</span>
</td></tr>
<tr class="Last">
<td> RA<br> RARS<br> <span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span><br> <span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>-t<br> CMML </td>
<td align="center">12 (13)<br>7 (8)<br>47 (53)<br>17 (19)<br>6 (7)</td>
<td align="center">12 (15)<br>4 (5)<br>43 (53)<br>14 (17)<br>8 (10)</td>
</tr>
</tbody>
</table>
<p>    Patients randomized to the Dacogen arm received Dacogen intravenously infused at a dose of 15 mg/m<span class="Sup">2</span> over a 3-hour period, every 8 hours, for 3 consecutive days.  This cycle was repeated every 6 weeks, depending on the patient’s clinical response and toxicity.  Supportive care consisted of blood and blood product transfusions, <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> antibiotics, and hematopoietic growth factors.  The study endpoints were overall response rate (complete response + partial response) and time to AML or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.  Responses were classified using the MDS International Working Group (IWG) criteria; patients were required to be RBC and platelet transfusion independent during the time of response.  Response criteria are given in <span class="Bold">Table 5</span>: </p>
<table>
<caption><span>Table 5 Response Criteria for Phase 3 MDS Trial* </span></caption>
<col>
<col>
<col>
<tfoot><tr class="First Last"><td colspan="3">  *Cheson BD, Bennett JM, et al. Report of an International Working Group to Standardize Response Criteria for MDS. <span class="Italics">Blood.</span> 2000; 96:3671-3674. </td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule" rowspan="2" valign="top"> <span class="Bold">Complete Response (CR)</span><br><span class="Bold">≥ 8 weeks</span>
</td>
<td class="Botrule Lrule Rrule" valign="top"> <span class="Bold">Bone Marrow</span>
</td>
<td class="Botrule Lrule Rrule" valign="top"> <span class="Bold">On repeat aspirates:</span><ul class="Disk">
<li>&lt; 5% myeloblasts 
</li>
<li>No dysplastic changes</li>
</ul>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"> <span class="Bold">Peripheral Blood</span>
</td>
<td class="Botrule Lrule Rrule" valign="top"> <span class="Bold">In all samples during response:</span><ul class="Disk">
<li>Hgb &gt; 11 g/dL (no transfusions or erythropoietin 
</li>
<li>ANC ≥ 1500/μL (no growth factor) 
</li>
<li>Platelets ≥ 100,000/μL (no thrombopoietic agent) 
</li>
<li>No blasts and no <span class="product-label-link" type="condition" conceptid="4093447" conceptname="Dysplasia">dysplasia</span></li>
</ul>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" rowspan="2" valign="top"> <span class="Bold">Partial Response (PR)</span><br><span class="Bold">≥ 8 weeks</span>
</td>
<td class="Botrule Lrule Rrule" valign="top"> <span class="Bold">Bone Marrow</span>
</td>
<td class="Botrule Lrule Rrule" valign="top"> <span class="Bold">On repeat aspirates:</span><ul class="Disk">
<li>≥ 50% decrease in blasts over pretreatment values<br>OR 
</li>
<li>Improvement to a less advanced MDS FAB classification</li>
</ul>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"> <span class="Bold">Peripheral Blood</span>
</td>
<td class="Botrule Lrule Rrule" valign="top"> <span class="Bold">Same as for CR</span>
</td>
</tr>
</tbody>
</table>
<p>    The overall response rate (CR+PR) in the ITT population was 17% in Dacogen-treated patients and 0% in the SC group (p&lt;0.001).  (<span class="Bold">See</span><span class="Bold">Table 6</span>) The overall response rate was 21% (12/56) in Dacogen-treated patients considered evaluable for response (i.e., those patients with pathologically confirmed MDS at baseline who received at least 2 cycles of treatment).  The median duration of response (range) for patients who responded to Dacogen was 288 days (116-388) and median time to response (range) was 93 days (55-272).  All but one of the Dacogen-treated patients who responded did so by the fourth cycle.  Benefit was seen in an additional 13% of Dacogen-treated patients who had hematologic improvement, defined as a response less than PR lasting at least 8 weeks, compared to 7% of SC patients.  Dacogen treatment did not significantly delay the median time to AML or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> versus supportive care.</p>
<table>
<caption><span>Table 6 Analysis of Response (ITT) </span></caption>
<col>
<col>
<col>
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule" align="center">Parameter </th>
<th class="Botrule Lrule Rrule" align="center">Dacogen<br>N=89 </th>
<th class="Botrule Lrule Rrule" align="center">Supportive Care<br>N=81 </th>
</tr></thead>
<tfoot><tr class="First Last"><td colspan="3">  **p-value &lt;0.001 from two-sided Fisher's Exact Test comparing Dacogen vs. Supportive Care.<br><span class="Sup">  †</span>In the statistical analysis plan, a p-value of ≤ 0.024 was required to achieve statistical significance. </td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule Rrule"> <span class="Bold">Overall Response Rate (CR+PR)<span class="Sup">†</span></span>
</td>
<td class="Lrule Rrule" align="center"> <span class="Bold">15 (17%)**</span>
</td>
<td class="Lrule Rrule" align="center"><span class="Bold">0 (0%)</span></td>
</tr>
<tr>
<td class="Lrule Rrule">      Complete Response (CR) </td>
<td class="Lrule Rrule" align="center">  8 (9%) </td>
<td class="Lrule Rrule" align="center">0 (0%)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule">      Partial Response (PR) </td>
<td class="Botrule Lrule Rrule" align="center">  7 (8%) </td>
<td class="Botrule Lrule Rrule" align="center">0 (0%)</td>
</tr>
<tr>
<td class="Lrule Rrule"> <span class="Bold">Duration of Response</span>
</td>
<td class="Lrule Rrule" align="center"> </td>
<td class="Lrule Rrule" align="center"> </td>
</tr>
<tr>
<td class="Lrule Rrule">  Median time to (CR+PR) response - Days (range) </td>
<td class="Lrule Rrule" align="center">  93 (55-272) </td>
<td class="Lrule Rrule" align="center">  NA </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule">  Median Duration of (CR+PR) response - Days (range) </td>
<td class="Botrule Lrule Rrule" align="center">  288 (116-388) </td>
<td class="Botrule Lrule Rrule" align="center">  NA </td>
</tr>
</tbody>
</table>
<p>All patients with a CR or PR were RBC and platelet transfusion independent in the absence of growth factors.</p>
<p>Responses occurred in patients with an adjudicated baseline diagnosis of AML.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_799a73a7-dffe-444f-a91b-a725b42db3a8"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Single-arm Studies</h2>
<p class="First">    Three open-label, single-arm, multicenter studies were conducted to evaluate the safety and efficacy of Dacogen in MDS patients with any of the FAB subtypes. In one study conducted in North America, 99 patients with IPSS Intermediate-1, Intermediate-2, or high risk prognostic scores received Dacogen by intravenous infusion at a dose of 20 mg/m<span class="Sup">2</span> IV over 1-hour daily, on days 1-5 of week 1 every 4 weeks (1 cycle).  The results were consistent with the results of the controlled trial and summarized in Table 8.</p>
<table>
<caption><span>Table 7 Baseline Demographics and Other Patient Characteristics (ITT)</span></caption>
<col>
<col>
<thead><tr class="First Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Demographic or Other Patient Characteristic</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"><span class="Bold">Dacogen<br></span><span class="Bold">N = 99</span></p></td>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Age (years)<br></span>Mean (±SD)<br>Median (Range:  min-max)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>71±9<br>72 (34-87)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Gender n (%)<br></span>Male <br>Female</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>71 (72)<br>28 (28)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Race n (%)<br></span>White<br>Black<br>Asian<br>Other</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>86 (87)<br>6  (6)<br>4  (4)<br>3  (3)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Days From MDS Diagnosis to First Dose<br></span>Mean (±SD)<br>Median (Range:  min-max)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>444±626<br>154 (7-3079)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Previous MDS Therapy n (%)<br></span>Yes <br>No</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>27 (27)<br>72 (73)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">RBC Transfusion Status n (%)<br></span>Independent <br>Dependent</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>33 (33)<br>66 (67)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Platelet Transfusion Status n (%)<br></span>Independent<br>Dependent </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>84 (85)<br>15 (15)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">IPSS Classification n (%)<br></span>Low Risk<br>Intermediate–1<br>Intermediate–2 <br>High Risk</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>1  (1)<br>52 (53)<br>23 (23)<br>23 (23)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">FAB Classification n (%)<br></span>RA<br>RARS <br><span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span> <br><span class="product-label-link" type="condition" conceptid="136949" conceptname="Refractory anemia with excess blasts">RAEB</span>-t<br>CMML</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>20 (20)<br>17 (17)<br>45 (45)<br>6 (6)<br>11 (11)</p></td>
</tr>
</tbody>
</table>
<table>
<caption><span>Table 8 Analysis of Response (ITT)*</span></caption>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">Parameter</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold"> Dacogen<br></span><span class="Bold">N=99</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Overall Response Rate (CR+PR)<br></span>     Complete Response (CR)<br>     Partial Response (PR)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First"><span class="Bold">16 (16%)<br></span>15 (15%)<br>1 (1%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule"><p class="First"><span class="Bold">Duration of Response<br></span>Median time to (CR+PR) response - Days (range)<br>Median Duration of (CR+PR) response - Days (range)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First"> <br>162 (50-267)<br>443 (72-722+)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule Toprule" colspan="2"> + indicates censored observation <br> * Cheson BD, Bennett JM, et al. Report of an International Working Group to <br>Standardize Response Criteria for MDS. <span class="Italics">Blood</span>. 2000; 96:3671-3674.</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_c166a9af-307b-4cec-9722-7ce34db4697d"></a><a name="section-14"></a><p></p>
<h1>15 REFERENCES</h1>
<ol class="Arabic">
<li>NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.</li>
<li>OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling Occupational Exposure to Hazardous Drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.html</li>
<li>American Society of Health-System Pharmacists. ASHP Guidelines on Handling Hazardous Drugs: <span class="Italics">Am J Health-Syst Pharm</span>. 2006;63:1172-1193.</li>
<li>Polovich M., White JM, Kelleher LO (eds). Chemotherapy and biotherapy guidelines and recommendations for practice (2nd ed.) 2005. Pittsburgh, PA: Oncology Nursing Society.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_8d3108b6-1dcf-4244-b091-6815efbc6f1e"></a><a name="section-15"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">    NDC 62856-600-01, 50 mg single-dose vial individually packaged in a carton.</p>
<p><span class="Bold">Storage<br>    </span>Store vials at 25°C (77°F); excursions permitted to 15-30°C (59-86°F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_a988db01-2eb6-4cfa-896d-839fd6d10dd0"></a><a name="section-16"></a><p></p>
<h1>
17 PATIENT COUNSELING INFORMATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9f0c7469-983d-4788-8e4e-1f642d547156"></a><a name="section-16.1"></a><p></p>
<h2>Instructions for Patients</h2>
<p class="First">    Women of childbearing potential should be advised to avoid becoming pregnant while receiving treatment with Dacogen and for I month afterwards, and to use effective contraception during this time, <span class="Italics">[See Warnings and Precautions (<a href="#LINK_186f0929-785d-453c-a029-4d218422a281">5.3</a>)]</span>.</p>
<p>    Men should be advised not to father a child while receiving treatment with Dacogen, and for 2 months afterwards. During these times, men with female partners of childbearing potential should use effective contraception <span class="Italics">[See Warnings and Precautions (<a href="#LINK_000d2292-72c8-4815-afc9-884bc6eb9ad8">5.4</a>) and Nonclinical Toxicology (<a href="#LINK_6e12c1c0-16b8-46a7-a760-fdfb87bfbde6">13.1</a>)]</span>.</p>
<p>    Patients should be advised to monitor and report any symptoms of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, or <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> to their physician as soon as possible <span class="Italics">[See Warnings and Precautions (<a href="#LINK_c926a46e-9f18-43ec-b768-f43242d43eab">5.1</a>)]</span>.</p>
<p>Eisai Inc.<br>Manufactured by Pharmachemie B.V. Haarlem, The Netherlands<br>Manufactured for Eisai Inc., Woodcliff Lake, NJ 07677</p>
<p>Dacogen® is a registered trademark of Astex Pharmaceuticals, Inc., <br>Dublin, CA, U.S.A. used under license.</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_d61186ad-8ae1-45b8-878c-536774f00b36"></a><a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 62856-600-01</p>
<p>DACOGEN<span class="Sub">®</span><br>decitabine for injection<br>50 mg per vial</p>
<p>FOR INTRAVENOUS USE ONLY<br>WARNING: Cytotoxic Agent<br>Single use sterile vial</p>
<p>Rx ONLY</p>
<div class="Figure"><img alt="NDC 62856-600-01 DACOGEN® decitabine for injection 50 mg per vial FOR INTRAVENOUS USE ONLY WARNING: Cytotoxic Agent Single use sterile vial Rx ONLY" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2&amp;name=dacogen-2.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_ef5f80a3-525b-4460-90ba-85461dcf6c30"></a><a name="section-18"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First">NDC 62856-600-01</p>
<p>DACOGEN<span class="Sub">®</span><br>decitabine for injection<br>50 mg per vial</p>
<p>FOR INTRAVENOUS USE ONLY<br>WARNING: Cytotoxic Agent<br>Single use sterile vial</p>
<p>Rx ONLY</p>
<div class="Figure"><img alt="NDC 62856-600-01 DACOGEN® decitabine for injection 50 mg per vial FOR INTRAVENOUS USE ONLY WARNING: Cytotoxic Agent Single use sterile vial Rx ONLY" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2&amp;name=dacogen-3.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DACOGEN 		
					</strong><br><span class="contentTableReg">decitabine injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62856-600</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>DECITABINE</strong> (DECITABINE) </td>
<td class="formItem">DECITABINE</td>
<td class="formItem">50 mg  in 20 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POTASSIUM PHOSPHATE, MONOBASIC</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62856-600-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">20 mL in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021790</td>
<td class="formItem">05/03/1996</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Eisai Inc.
							(831600833)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Pharmachemie B.V.</td>
<td class="formItem"></td>
<td class="formItem">402108922</td>
<td class="formItem">MANUFACTURE(62856-600)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9178b403-6b09-47f8-a88c-f2a58e1d06c9</div>
<div>Set id: acaf6e50-7cd3-4431-98ef-d1c07e3ed8c2</div>
<div>Version: 7</div>
<div>Effective Time: 20140228</div>
</div>
</div> <div class="DistributorName">Eisai Inc.</div></p>
</body></html>
